{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:22:26Z","timestamp":1761513746199},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jtoelsevier.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jtho.2015.09.007","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T09:06:14Z","timestamp":1451898374000},"page":"115-121","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Are Anthracycline-Based Regimens Truly Indicated To\u00a0Be the Standard Chemotherapy Regimen for Thymic\u00a0Carcinoma?"],"prefix":"10.1016","volume":"11","author":[{"given":"Fumihiko","family":"Hirai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Toyozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Nosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2015.09.007_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"de Jong","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2015.09.007_bib4","series-title":"World Health Organization Classification of Tumours","first-page":"145","article-title":"Tumours of the lung, pleura, thymus and heart. Pathology and Genetics","author":"Travis","year":"2004"},{"key":"10.1016\/j.jtho.2015.09.007_bib5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjc.6690773","article-title":"Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience","volume":"81","author":"Berruti","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00000421-200206000-00012","article-title":"Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy)","volume":"25","author":"Koizumi","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib7","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/JTO.0b013e3181db3dee","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience","volume":"5","author":"Grassin","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/cncr.11606","article-title":"Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma","volume":"98","author":"Yoh","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib11","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2003.12.010","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib14","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib15","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000421-199308000-00014","article-title":"EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma","volume":"16","author":"Bonomi","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib17","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002371-199510000-00005","article-title":"A\u00a0phase II trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed\/refractory thymoma","volume":"18","author":"Gordon","year":"1995","journal-title":"J\u00a0Immunother Emphasis Tumor Immunol"},{"key":"10.1016\/j.jtho.2015.09.007_bib19","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2003.09.022","article-title":"Multimodal management of stages III\u2013IVa malignant thymoma","volume":"44","author":"Bretti","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib21","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H","article-title":"Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma","volume":"68","author":"Macchiarini","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7326\/0003-4819-129-2-199807150-00006","article-title":"A\u00a0multidisciplinary approach to therapy for unresectable malignant thymoma","volume":"129","author":"Shin","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtho.2015.09.007_bib24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605347","article-title":"A\u00a0phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)","volume":"101","author":"Kunitoh","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjc.6605731","article-title":"A\u00a0phase II trial of dose-dense chemotherapy, followed by surgical resection and\/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)","volume":"103","author":"Kunitoh","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/01.coc.0000046301.83671.09","article-title":"Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience","volume":"27","author":"Hernandez-Ilizaliturri","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.athoracsur.2004.12.047","article-title":"Advanced stage thymomas and thymic carcinomas: results of multimodality treatments","volume":"79","author":"Lucchi","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2015.09.007_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/JTO.0b013e31802bafc8","article-title":"Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone","volume":"2","author":"Yokoi","year":"2007","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib29","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1990.8.8.1419","article-title":"Chemotherapy of invasive thymoma","volume":"8","author":"Fornasiero","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-5223(19)34092-9","article-title":"Chemotherapy and operation for invasive thymoma","volume":"106","author":"Rea","year":"1993","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2015.09.007_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/annonc\/mdl377","article-title":"Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus\u00a0paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non\u2013small-cell lung cancer: Four-Arm Cooperative Study in Japan","volume":"18","author":"Ohe","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A\u00a0multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/JTO.0b013e318292c41e","article-title":"A\u00a0prospective phase II trial of induction chemotherapy with docetaxel\/cisplatin for Masaoka stage III\/IV thymic epithelial tumors","volume":"8","author":"Park","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000097944","article-title":"Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients","volume":"70","author":"Maruyama","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.jtho.2015.09.007_bib35","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hyr089","article-title":"Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer","volume":"41","author":"Furugen","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2011.05.013","article-title":"Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity","volume":"74","author":"Okuma","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2015.09.007_bib38","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1245\/s10434-010-1134-9","article-title":"New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma: a retrospective analysis","volume":"17","author":"Mineo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib39","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A\u00a0multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207 L","volume":"26","author":"Hirai","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2015.09.007_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what it is and what it isn't","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T13:43:07Z","timestamp":1600004587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1556086415000143"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2015.09.007","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are Anthracycline-Based Regimens Truly Indicated To\u00a0Be the Standard Chemotherapy Regimen for Thymic\u00a0Carcinoma?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2015.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}